Status:
COMPLETED
of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation
Lead Sponsor:
Banaras Hindu University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-99 years
Brief Summary
Androgen Receptor is extensively expressed in BRCA and its role in the disease may differ depending upon molecular subtypes and stages. Androgen Receptor (AR) may act as an antagonist of estrogen rece...
Detailed Description
The rate of AR positivity in breast cancer is about 60% to 80%. Biologically the AR pathway has cross talk with several other key signaling pathway, including the PI3K/Akt/mTOR and MAPK Pathways, and ...
Eligibility Criteria
Inclusion
- Histology proven cases of breast cancer
Exclusion
- Patients with prior treatment
- Pregnant and lactating women
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT05404334
Start Date
July 1 2021
End Date
July 1 2024
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Banaras Hindu University
Varanasi, Uttar Pradesh, India, 221005